Tumor-Targeted Bispecific CD28 Antigen Binding Molecules Patent Grant
Summary
USPTO granted patent US12600781B2 to Hoffmann-La Roche Inc. covering tumor-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28. The patent includes 51 claims covering the binding molecules, methods of production, pharmaceutical compositions containing these antibodies, and methods of using the same for cancer treatment.
What changed
USPTO granted patent US12600781B2 to Hoffmann-La Roche Inc. for tumor-targeted bispecific agonistic CD28 antigen binding molecules. The invention is characterized by monovalent binding to CD28 and includes 51 claims covering the binding molecules, methods of production, pharmaceutical compositions, and cancer treatment methods.
Pharmaceutical companies developing cancer immunotherapy treatments involving CD28 or bispecific antibodies should monitor this patent for potential licensing considerations or freedom-to-operate analysis. The patent provides intellectual property protection for the assignee and does not create immediate compliance obligations for third parties.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tumor-targeted agonistic CD28 antigen binding molecules
Grant US12600781B2 Kind: B2 Apr 14, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
Abstract
The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
CPC Classifications
C07K 16/2818 C07K 2317/31 C07K 2317/75 C07K 16/2803 C07K 16/2809 C07K 16/2827 C07K 16/286 C07K 16/2878 C07K 16/2896 C07K 16/30 C07K 16/3007 C07K 16/32 C07K 16/40 C07K 2317/24 C07K 2317/35 C07K 2317/52 C07K 2317/526 C07K 2317/55 C07K 2317/565 C07K 2317/70 C07K 2317/73 C07K 2317/92 A61P 35/00 A61K 2039/505 A61K 2039/507
Filing Date
2022-11-17
Application No.
18056655
Claims
51
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from Hoffmann-La Roche.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.